BMO Downgrades Gilead Sciences (GILD) to Market Perform
BMO Capital downgrades Gilead Sciences (Nasdaq: GILD) from Outperform to Market Perform.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Related Categories
DowngradesStocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
